Compounds > metformin
Page last updated: 2024-10-30

metformin and Chronic Illness

metformin has been researched along with Chronic Illness in 52 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
" placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs."9.41The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021)
"A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6."9.22Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016)
"Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients."9.13Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008)
"Aim of the investigation was to study safety of therapy with metformin and its effect on clinical, hemodynamic, functional and neurohumoral status in patients with chronic heart failure and type 2 diabetes mellitus DM)."9.13[Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study "rational effective mulicomponent therapy in the battle against diabetes mellitus in patients with chronic heart failure ( Arzamastseva, NE; Baklanova, NA; Belenkov, IuN; Bolotina, MG; Lapina, IuV; Litonova, GN; Mareev, VIu; Masenko, VP; Narusov, OIu; Shestakova, MV, 2008)
"To synthesize data addressing outcomes of metformin use in populations with type 2 diabetes and moderate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment."8.95Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. ( Cameron, CB; Crowley, MJ; Diamantidis, CJ; Kosinski, AS; McDuffie, JR; Mock, CK; Nagi, A; Stanifer, JW; Tang, S; Wang, X; Williams, JW, 2017)
"Methods based on atomic force microscopy (AFM) were used to directly evaluate the influence of metformin on the nanomechanical and adhesive properties of endothelial and cancer cells in chronic hyperglycemia."7.96Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier. ( Grochot-Przeczek, A; Kloska, D; Malek-Zietek, KE; Rajfur, Z; Stepien, EŁ; Szymonski, M; Targosz-Korecka, M, 2020)
"One thousand sixty-four limbs in 1204 patients were identified (147 metformin, 196 other hypoglycemics [OH], 216 insulin, and 645 nondiabetics (nondiabetes mellitus [DM])."7.91Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease. ( Cherr, GS; Dosluoglu, HH; Dryjski, ML; Harris, LM; Khan, SZ; Nader, ND; Rivero, M, 2019)
"Our data suggest that pre-existing non-symptomatic gastritis was associated with metformin-related gastrointestinal side effects."7.81Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes. ( Huang, Y; Sun, J; Tan, W; Tao, X; Wang, H; Wang, X, 2015)
" All cases of lactic acidosis (pH, ≤ 7."7.80Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. ( Giampreti, A; Locatelli, CA; Lonati, D; Manzo, L; Papa, P; Petrolini, VM; Protti, A; Rocchi, L; Rognoni, C; Rolandi, L; Valli, A; Vecchio, S, 2014)
"Pregnant women with Type 2 DM who were treated with metformin had more risk factors for adverse pregnancy outcomes, but no differences in outcomes were seen compared with women not taking metformin."7.73Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? ( Hughes, RC; Rowan, JA, 2006)
" We are conducting a randomized clinical trial to test the effect of a Mediterranean dietary intervention with or without 1700 mg/day of metformin for the prevention of age-related chronic diseases, the MeMeMe trial (Trial registration number: EudraCT number: 2012-005427-32 ClinicalTrials."5.51Recruitment in randomized clinical trials: The MeMeMe experience. ( Baldassari, I; Berrino, F; Bruno, E; Casagrande, A; Cortellini, M; Del Sette Cerulli, D; Di Mauro, MG; Gargano, G; Krogh, V; Manuela, B; Oliverio, A; Pasanisi, P; Venturelli, E, 2022)
" placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs."5.41The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021)
"Metformin is a biguanide group oral antidiabetic drug used for the treatment of type 2 diabetes mellitus."5.40Lactic acidosis induced by metformin in a chronic hemodialysis patient with diabetes mellitus type 2. ( Altun, E; Karayaylalı, I; Kaya, B; Paydaş, S; Sarıakçalı, B, 2014)
"Insulin resistance is a recently identified mechanism involved in the pathophysiology of chronic heart failure (CHF)."5.38Metformin prevents the development of chronic heart failure in the SHHF rat model. ( Aimaretti, G; Cittadini, A; Isgaard, J; Longobardi, S; Monti, MG; Napoli, R; Netti, PA; Rea, D; Saccà, L; Samà, M; Walser, M, 2012)
"In 84% of the cases, type 2 diabetes mellitus has been present before the HCC diagnosis."5.36Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. ( Balbi, M; Casarin, P; Donadon, V; Mas, MD; Zanette, G, 2010)
"Metformin effects were analysed in hypoxia- and monocrotaline-induced PAH in rats."5.35Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. ( Agard, C; Dumas-de-La-Roque, E; Loirand, G; Pacaud, P; Rio, M; Rolli-Derkinderen, M; Sagan, C; Savineau, JP, 2009)
"Metformin is an effective and commonly administered drug for controlling plasma glucose concentrations in patients with type 2 diabetes mellitus."5.31Metformin as a cause of late-onset chronic diarrhea. ( Clement, KD; Foss, MT, 2001)
"A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6."5.22Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016)
"Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients."5.13Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008)
"Aim of the investigation was to study safety of therapy with metformin and its effect on clinical, hemodynamic, functional and neurohumoral status in patients with chronic heart failure and type 2 diabetes mellitus DM)."5.13[Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study "rational effective mulicomponent therapy in the battle against diabetes mellitus in patients with chronic heart failure ( Arzamastseva, NE; Baklanova, NA; Belenkov, IuN; Bolotina, MG; Lapina, IuV; Litonova, GN; Mareev, VIu; Masenko, VP; Narusov, OIu; Shestakova, MV, 2008)
"Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility."5.11Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004)
"To synthesize data addressing outcomes of metformin use in populations with type 2 diabetes and moderate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment."4.95Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. ( Cameron, CB; Crowley, MJ; Diamantidis, CJ; Kosinski, AS; McDuffie, JR; Mock, CK; Nagi, A; Stanifer, JW; Tang, S; Wang, X; Williams, JW, 2017)
"The FDA approved 'label' for metformin lists hepatic insufficiency as a risk for lactic acidosis."3.96The safety and pharmacokinetics of metformin in patients with chronic liver disease. ( Braithwaite, HE; Carland, JE; Cheng, TS; Danta, M; Day, RO; Graham, GG; Greenfield, JR; Kumar, SS; Liu, Z; Smith, FC; Stocker, SL; Williams, KM, 2020)
"Methods based on atomic force microscopy (AFM) were used to directly evaluate the influence of metformin on the nanomechanical and adhesive properties of endothelial and cancer cells in chronic hyperglycemia."3.96Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier. ( Grochot-Przeczek, A; Kloska, D; Malek-Zietek, KE; Rajfur, Z; Stepien, EŁ; Szymonski, M; Targosz-Korecka, M, 2020)
"One thousand sixty-four limbs in 1204 patients were identified (147 metformin, 196 other hypoglycemics [OH], 216 insulin, and 645 nondiabetics (nondiabetes mellitus [DM])."3.91Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease. ( Cherr, GS; Dosluoglu, HH; Dryjski, ML; Harris, LM; Khan, SZ; Nader, ND; Rivero, M, 2019)
"Members of the Hospital Italiano de Buenos Aires private health insurance, who had received a new electronic prescription (alendronate or ibandronate for secondary prevention of fractures following an osteoporotic fracture; insulin and/or metformin for type 2 diabetes; or tamoxifen as a treatment for breast cancer) during the years 2012 and 2013."3.88[Evaluation of primary adherence to medications in patients with chronic conditions: A retrospective cohort study]. ( Esteban, S; Peper, FE; Terrasa, SA, 2018)
"To evaluate the impact of depression on NASH through the involvement of JNK1 and to assess the effect of sitagliptin and metformin on hepatic JNK1 expression in both NASH and NASH associated with depression."3.85Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. ( Abd-Elaziz, LF; Aboul-Fotouh, S; El-Kharashi, OA; Magdy, YM; Nabih, ES; Shaker, SM, 2017)
"Our data suggest that pre-existing non-symptomatic gastritis was associated with metformin-related gastrointestinal side effects."3.81Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes. ( Huang, Y; Sun, J; Tan, W; Tao, X; Wang, H; Wang, X, 2015)
"We explored if known risk factors for pancreatic cancer such as type II diabetes and chronic inflammation, influence the pathophysiology of an established primary tumor in the pancreas and if administration of metformin has an impact on tumor growth."3.81Impact of diabetes type II and chronic inflammation on pancreatic cancer. ( Albert, AC; Amme, J; Bürtin, F; Partecke, LI; Radecke, T; Vollmar, B; Zechner, D, 2015)
" All cases of lactic acidosis (pH, ≤ 7."3.80Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. ( Giampreti, A; Locatelli, CA; Lonati, D; Manzo, L; Papa, P; Petrolini, VM; Protti, A; Rocchi, L; Rognoni, C; Rolandi, L; Valli, A; Vecchio, S, 2014)
"Pregnant women with Type 2 DM who were treated with metformin had more risk factors for adverse pregnancy outcomes, but no differences in outcomes were seen compared with women not taking metformin."3.73Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? ( Hughes, RC; Rowan, JA, 2006)
" Studies over the last decade have focused on the design and development of advanced oral delivery dosage forms using bio nano technologies and novel drug carrier systems."2.82Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions. ( Al-Salami, H; Atlas, MD; Brown, D; Chester, J; Foster, T; Ionescu, CM; Johnston, E; Jones, M; Kovacevic, B; Kuthubutheen, J; Mikov, M; Mooranian, A; Wagle, SR; Walker, D, 2022)
" The potential for a drug-drug interaction was explored in two phase 1 clinical studies in subjects with T2DM to evaluate the pharmacokinetics and safety of metformin 1000 mg BID when administered with ranolazine 1000 mg BID (Study 1, N = 28) or ranolazine 500 mg BID (Study 2, N = 25) as compared to metformin alone."2.80Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. ( Allard, M; Ben-Yehuda, O; Berg, J; Gottwald, M; Jochelson, P; Juan, A; Pannacciulli, N; Shao, Y; Zack, J; Zhang, H, 2015)
"Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease."2.71Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. ( Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D, 2003)
"Mycophenolic acid was detected in all cats."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Obesity is a chronic metabolic disorder that affects one third of American adults."2.44Pharmacotherapy for obesity. ( Aronne, LJ; Neff, LM, 2007)
" Results showed that metformin reduces the expression of RNase 7 in in vitro treated keratinocytes, suggesting that the chronic use of metformin should be evaluated in DFU patients, whereas calcitriol, phenyl butyrate and L-isoleucine did not increase the RNase 7 production."1.56Host Defense Peptide RNase 7 Is Down-regulated in the Skin of Diabetic Patients with or without Chronic Ulcers, and its Expression is Altered with Metformin. ( Enciso-Moreno, JA; Gonzalez-Curiel, I; Marin-Luevano, S; Rivas-Santiago, B; Rivas-Santiago, C; Rodríguez-Carlos, A; Santos-Mena, A; Torres-Juarez, F; Trujillo, V; Zaga-Clavellina, V, 2020)
"We propose definitions of the different states of waiting, persistence, with sufficient supply to implement the prescribed dosing regimen, gaps, nonpersistence, and nonacceptance and an algorithm for transitions between states to describe long-term adherence to medication treatment."1.40A multistate model and an algorithm for measuring long-term adherence to medication: a case of diabetes mellitus type 2. ( Aagaard, L; Carstensen, B; Hansen, EH; Jensen, ML; Jørgensen, ME, 2014)
"Metformin is a biguanide group oral antidiabetic drug used for the treatment of type 2 diabetes mellitus."1.40Lactic acidosis induced by metformin in a chronic hemodialysis patient with diabetes mellitus type 2. ( Altun, E; Karayaylalı, I; Kaya, B; Paydaş, S; Sarıakçalı, B, 2014)
"Insulin resistance is a recently identified mechanism involved in the pathophysiology of chronic heart failure (CHF)."1.38Metformin prevents the development of chronic heart failure in the SHHF rat model. ( Aimaretti, G; Cittadini, A; Isgaard, J; Longobardi, S; Monti, MG; Napoli, R; Netti, PA; Rea, D; Saccà, L; Samà, M; Walser, M, 2012)
"In 84% of the cases, type 2 diabetes mellitus has been present before the HCC diagnosis."1.36Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. ( Balbi, M; Casarin, P; Donadon, V; Mas, MD; Zanette, G, 2010)
"Metformin effects were analysed in hypoxia- and monocrotaline-induced PAH in rats."1.35Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. ( Agard, C; Dumas-de-La-Roque, E; Loirand, G; Pacaud, P; Rio, M; Rolli-Derkinderen, M; Sagan, C; Savineau, JP, 2009)
"The development of acute renal failure significantly complicates intravascular contrast medium (CM) use and is linked with high morbidity and mortality."1.34Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. ( Barrett, B; Benko, A; Capusten, B; Fraser-Hill, M; Magner, P; Myers, A; Owen, RJ, 2007)
"Metformin is an effective and commonly administered drug for controlling plasma glucose concentrations in patients with type 2 diabetes mellitus."1.31Metformin as a cause of late-onset chronic diarrhea. ( Clement, KD; Foss, MT, 2001)
"Chronic diarrhea was diagnosed in 32 patients (overall prevalence of 3."1.30The prevalence of chronic diarrhea among diabetic patients. ( Goldin, E; Israeli, E; Lysy, J, 1999)

Research

Studies (52)

TimeframeStudies, this research(%)All Research%
pre-19902 (3.85)18.7374
1990's1 (1.92)18.2507
2000's16 (30.77)29.6817
2010's25 (48.08)24.3611
2020's8 (15.38)2.80

Authors

AuthorsStudies
Jones, M1
Ionescu, CM1
Walker, D1
Wagle, SR1
Kovacevic, B1
Chester, J1
Foster, T1
Johnston, E1
Kuthubutheen, J1
Brown, D2
Atlas, MD1
Mikov, M1
Mooranian, A1
Al-Salami, H1
Baldassari, I1
Oliverio, A1
Krogh, V1
Bruno, E1
Gargano, G1
Cortellini, M1
Casagrande, A1
Di Mauro, MG1
Venturelli, E1
Del Sette Cerulli, D1
Manuela, B1
Berrino, F1
Pasanisi, P1
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B2
Wu, C1
Zhang, Z2
Yan, K1
Li, C3
Li, Y9
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J13
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J4
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Z2
Wang, Y6
Hu, X2
Li, Z5
Shen, Y1
Hu, D1
Chen, H2
Wu, X2
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z2
Zhang, X6
Yang, X4
Zhang, J5
Wang, H4
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H4
Xing, Z1
Lu, G1
Chen, D2
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y2
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J6
Geng, Y1
Zhang, Y7
Wang, X9
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S2
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C3
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C4
Zhao, W1
Xia, X1
Jiang, Y2
Peng, J1
Jia, Z1
Li, F2
Chen, X3
Mo, J1
Zhang, S4
Li, X11
Huang, T2
Zhu, Q1
Wang, S3
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G3
Frew, R1
Guo, X1
Gong, Q2
Borowiec, J1
Han, S1
Zhang, M5
Willis, M1
Kreouzis, T1
Yu, K2
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q3
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S2
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J4
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S2
Deng, W1
Wu, D4
Zhang, Q3
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H3
Xu, C3
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Targosz-Korecka, M1
Malek-Zietek, KE1
Kloska, D1
Rajfur, Z1
Stepien, EŁ1
Grochot-Przeczek, A1
Szymonski, M1
Smith, FC1
Stocker, SL1
Danta, M1
Carland, JE1
Kumar, SS1
Liu, Z3
Greenfield, JR1
Braithwaite, HE1
Cheng, TS1
Graham, GG1
Williams, KM1
Day, RO1
Liu, Y5
Bai, F1
Liu, N1
Qin, F1
Tu, T1
Li, B3
Ma, Y3
Ouyang, F1
Liu, Q2
Rodríguez-Carlos, A1
Trujillo, V1
Gonzalez-Curiel, I1
Marin-Luevano, S1
Torres-Juarez, F1
Santos-Mena, A1
Rivas-Santiago, C1
Enciso-Moreno, JA1
Zaga-Clavellina, V1
Rivas-Santiago, B1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S2
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y2
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Zhang, E1
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Meng, J1
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Zhou, X2
Wang, W1
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhang, L2
Zhuang, T1
Tu, J1
Qu, Y1
Yao, H1
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Yang, H1
Song, Y1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Rathore, MG1
Reddy, K1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Chen, W2
Zhang, F1
Wei, H1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T2
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC2
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Duong, F1
Kong, W1
Chang, JH1
Sun, J2
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Wiggers, H1
Køber, L1
Gislason, G1
Schou, M1
Poulsen, MK1
Vraa, S1
Nielsen, OW1
Bruun, NE1
Nørrelund, H1
Hollingdal, M1
Barasa, A1
Bøttcher, M1
Dodt, K1
Hansen, VB1
Nielsen, G1
Knudsen, AS1
Lomholdt, J1
Mikkelsen, KV1
Jonczy, B1
Brønnum-Schou, J1
Poenaru, MP1
Abdulla, J1
Raymond, I1
Mahboubi, K1
Sillesen, K1
Serup-Hansen, K1
Madsen, JS1
Kristensen, SL1
Larsen, AH1
Bøtker, HE1
Torp-Petersen, C1
Eiskjær, H1
Møller, J1
Hassager, C1
Steffensen, FH1
Bibby, BM1
Refsgaard, J1
Høfsten, DE1
Mellemkjær, S1
Gustafsson, F1
Peper, FE1
Esteban, S1
Terrasa, SA1
Packer, M1
Barengolts, E1
Green, SJ1
Eisenberg, Y1
Akbar, A1
Reddivari, B1
Layden, BT1
Dugas, L1
Chlipala, G1
Verspohl, E1
Khan, SZ1
Rivero, M1
Nader, ND1
Cherr, GS1
Harris, LM1
Dryjski, ML1
Dosluoglu, HH1
Al-Hashem, F1
Al-Humayed, S1
Amin, SN1
Kamar, SS1
Mansy, SS1
Hassan, S1
Abdel-Salam, LO1
Ellatif, MA1
Alfaifi, M1
Haidara, MA1
Al-Ani, B1
Vecchio, S1
Giampreti, A1
Petrolini, VM1
Lonati, D1
Protti, A1
Papa, P1
Rognoni, C1
Valli, A1
Rocchi, L1
Rolandi, L1
Manzo, L1
Locatelli, CA1
Altun, E1
Kaya, B1
Paydaş, S1
Sarıakçalı, B1
Karayaylalı, I1
Jensen, ML1
Jørgensen, ME1
Hansen, EH1
Aagaard, L1
Carstensen, B1
Zechner, D1
Radecke, T1
Amme, J1
Bürtin, F1
Albert, AC1
Partecke, LI1
Vollmar, B1
Tao, X1
Tan, W1
Weintraub, K1
Houssaini, A1
Abid, S1
Derumeaux, G1
Wan, F1
Parpaleix, A1
Rideau, D1
Marcos, E1
Kebe, K1
Czibik, G1
Sawaki, D1
Treins, C1
Dubois-Randé, JL1
Amsellem, V1
Lipskaia, L1
Pende, M1
Adnot, S1
Tanaka, A1
Kitakaze, M1
Oyama, J1
Sata, M1
Taguchi, I1
Shimizu, W1
Watada, H1
Tomiyama, H1
Ako, J1
Sakata, Y1
Anzai, T1
Uematsu, M1
Suzuki, M1
Eguchi, K1
Yamashina, A1
Saito, Y1
Sato, Y1
Ueda, S1
Murohara, T1
Node, K1
Zack, J1
Berg, J1
Juan, A1
Pannacciulli, N1
Allard, M1
Gottwald, M1
Shao, Y1
Ben-Yehuda, O1
Jochelson, P1
Magdy, YM1
El-Kharashi, OA1
Nabih, ES1
Shaker, SM1
Abd-Elaziz, LF1
Aboul-Fotouh, S1
Crowley, MJ1
Diamantidis, CJ1
McDuffie, JR1
Cameron, CB1
Stanifer, JW1
Mock, CK1
Nagi, A1
Kosinski, AS1
Williams, JW1
Riis, PT1
Ring, HC1
Themstrup, L1
Jemec, GB1
Wong, AK1
AlZadjali, MA1
Choy, AM1
Nath, N1
Khan, M1
Paintlia, MK1
Singh, I1
Hoda, MN1
Giri, S1
Agard, C1
Rolli-Derkinderen, M1
Dumas-de-La-Roque, E1
Rio, M1
Sagan, C1
Savineau, JP1
Loirand, G1
Pacaud, P1
Reach, G1
Blagosklonny, MV1
Donadon, V1
Balbi, M1
Mas, MD1
Casarin, P1
Zanette, G1
Pilmore, HL1
Raucoules, M1
Asehnoune, K1
Carles, M1
Deleuze, A1
González, O1
Tobia, C1
Ebersole, J1
Novak, MJ1
Cittadini, A1
Napoli, R1
Monti, MG1
Rea, D1
Longobardi, S1
Netti, PA1
Walser, M1
Samà, M1
Aimaretti, G1
Isgaard, J1
Saccà, L1
Dei Cas, A1
Spigoni, V1
Ridolfi, V1
Metra, M1
Varo, N1
Vicent, D1
Libby, P1
Nuzzo, R1
Calle-Pascual, AL1
Bernal, MR1
Fernández-Cruz, A1
Veves, A1
Jarolim, P1
Varo, JJ1
Goldfine, A1
Horton, E1
Schönbeck, U1
Bhasin, DK1
Sidhu, RS1
Bhansali, A1
Nagi, B1
Matsumoto, K1
Sera, Y1
Abe, Y1
Tominaga, T1
Yeki, Y1
Miyake, S1
Lazurova, I1
Dravecka, I1
Kraus, V1
Petrovicova, J1
Hughes, RC1
Rowan, JA1
Benko, A1
Fraser-Hill, M1
Magner, P1
Capusten, B1
Barrett, B1
Myers, A1
Owen, RJ1
Baptista, T2
Uzcátegui, E1
Rangel, N1
El Fakih, Y1
Galeazzi, T1
Beaulieu, S1
de Baptista, EA1
Neff, LM1
Aronne, LJ1
Lapina, IuV1
Narusov, OIu1
Mareev, VIu1
Bolotina, MG1
Shestakova, MV1
Masenko, VP1
Litonova, GN1
Arzamastseva, NE1
Baklanova, NA1
Belenkov, IuN1
Tikholov, K1
Kalpazanova, N1
Peshev, P1
Kostov, M1
Kusinikov, V1
Lysy, J1
Israeli, E1
Goldin, E1
Hernàndez, L1
Prieto, LA1
Boyero, EC1
de Mendoza, S1
Foss, MT1
Clement, KD1
Streda, M1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Controlled Trial of Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome[NCT02960711]Phase 31,600 participants (Actual)Interventional2014-02-28Completed
A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M[NCT03514108]Phase 41,500 participants (Anticipated)Interventional2018-03-01Recruiting
Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study[NCT03848533]Phase 242 participants (Anticipated)Interventional2019-08-22Recruiting
Empowerment, Motivation and Medical Adherence (EMMA). Dialogue Tools for Consultations With Patients With Type 2 Diabetes[NCT03008395]0 participants (Actual)Interventional2017-10-31Withdrawn (stopped due to Unable to secure clinic support for conducting research)
A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy[NCT04317287]9 participants (Actual)Interventional2019-12-10Terminated (stopped due to COVID-19 Pandemic)
Prospective, Double Blind, Randomized Trial: Meniscal Repair With or Without Augmentation Utilizing Platelet Rich Plasma.[NCT01991353]0 participants (Actual)Interventional2015-07-31Withdrawn (stopped due to Lack of funding)
The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate[NCT01210456]Phase 3458 participants (Anticipated)Interventional2009-10-31Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

15 reviews available for metformin and Chronic Illness

ArticleYear
Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions.
    International journal of molecular sciences, 2022, Jan-13, Volume: 23, Issue:2

    Topics: Biguanides; Bile Acids and Salts; Chronic Disease; Drug Carriers; Drug Compounding; Drug Delivery Sy

2022
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:7

    Topics: Chronic Disease; Comorbidity; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heart Failure; Humans;

2018
[In process].
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:10

    Topics: Aged; Aging; Animals; Chronic Disease; Humans; Hypoglycemic Agents; Metformin; Risk Factors

2016
Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.
    Annals of internal medicine, 2017, Feb-07, Volume: 166, Issue:3

    Topics: Cause of Death; Chronic Disease; Contraindications; Diabetes Mellitus, Type 2; Heart Failure; Humans

2017
The Role of Androgens and Estrogens in Hidradenitis Suppurativa - A Systematic Review.
    Acta dermatovenerologica Croatica : ADC, 2016, Volume: 24, Issue:4

    Topics: Adult; Age Distribution; Androgens; Chronic Disease; Denmark; Estrogens; Female; Hidradenitis Suppur

2016
Insulin resistance: a potential new target for therapy in patients with heart failure.
    Cardiovascular therapeutics, 2008,Fall, Volume: 26, Issue:3

    Topics: Chronic Disease; Heart Failure; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoli

2008
Validation of anti-aging drugs by treating age-related diseases.
    Aging, 2009, Mar-28, Volume: 1, Issue:3

    Topics: Aging; Animals; Antibiotics, Antineoplastic; Antioxidants; Biomarkers; Chronic Disease; Humans; Hypo

2009
Review: metformin: potential benefits and use in chronic kidney disease.
    Nephrology (Carlton, Vic.), 2010, Volume: 15, Issue:4

    Topics: Acidosis, Lactic; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Nephropathies;

2010
[Perioperative management of chronic treatment and medical devices. Endocrine pathology].
    Annales francaises d'anesthesie et de reanimation, 2011, Volume: 30, Issue:2

    Topics: Chronic Disease; Diabetes Mellitus; Endocrine System Diseases; Glucocorticoids; Humans; Hypoglycemic

2011
Caloric restriction and chronic inflammatory diseases.
    Oral diseases, 2012, Volume: 18, Issue:1

    Topics: Adaptive Immunity; Animals; Biomimetics; Caloric Restriction; Cardiovascular Diseases; Chronic Disea

2012
Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach.
    Endocrine, metabolic & immune disorders drug targets, 2013, Volume: 13, Issue:1

    Topics: Chronic Disease; Diabetes Mellitus; Diabetic Cardiomyopathies; Heart Failure; Humans; Hypoglycemic A

2013
Pharmacotherapy for obesity.
    Current atherosclerosis reports, 2007, Volume: 9, Issue:6

    Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclo

2007
Glucose tolerance tests in the clinical picture of chronic liver diseases.
    Acta Universitatis Carolinae. Medica. Monographia, 1975, Issue:67

    Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight

1975

Trials

11 trials available for metformin and Chronic Illness

ArticleYear
Recruitment in randomized clinical trials: The MeMeMe experience.
    PloS one, 2022, Volume: 17, Issue:3

    Topics: Chronic Disease; Female; Humans; Logistic Models; Metformin; Racial Groups; Research Design

2022
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr
    American heart journal, 2021, Volume: 231

    Topics: Aged; Chronic Disease; Denmark; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; H

2021
Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease.
    PloS one, 2018, Volume: 13, Issue:3

    Topics: Bacteria; Black or African American; Chronic Disease; Cost of Illness; Cross-Sectional Studies; Diab

2018
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Cardiovascular diabetology, 2016, Apr-04, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin;

2016
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
    Clinical pharmacology in drug development, 2015, Volume: 4, Issue:2

    Topics: Adult; Aged; Angina Pectoris; Animals; Area Under Curve; Cardiovascular Agents; CHO Cells; Chronic D

2015
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
    Circulation, 2003, Jun-03, Volume: 107, Issue:21

    Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Diseas

2003
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
    Bratislavske lekarske listy, 2004, Volume: 105, Issue:5-6

    Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu

2004
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Psychiatry research, 2008, May-30, Volume: 159, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease

2008
[Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study "rational effective mulicomponent therapy in the battle against diabetes mellitus in patients with chronic heart failure
    Kardiologiia, 2008, Volume: 48, Issue:3

    Topics: Administration, Oral; Aged; Blood Glucose; Catecholamines; Chronic Disease; Colorimetry; Diabetes Me

2008
Metformin in obesity associated with antipsychotic drug administration: a pilot study.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:8

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Area Under Curve; Blood Glucose; Body Mass Index; Brie

2001

Other Studies

27 other studies available for metformin and Chronic Illness

ArticleYear
Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier.
    Biochimica et biophysica acta. General subjects, 2020, Volume: 1864, Issue:4

    Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Cell Adhesion; Cells, Cultur

2020
The safety and pharmacokinetics of metformin in patients with chronic liver disease.
    Alimentary pharmacology & therapeutics, 2020, Volume: 51, Issue:5

    Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Chronic Disease; Comorbidity; Cross-Sectional Stud

2020
Metformin improves lipid metabolism and reverses the Warburg effect in a canine model of chronic atrial fibrillation.
    BMC cardiovascular disorders, 2020, 02-03, Volume: 20, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Atrial Appendage; Atrial Fibrillation; Atrial Function, Left

2020
Host Defense Peptide RNase 7 Is Down-regulated in the Skin of Diabetic Patients with or without Chronic Ulcers, and its Expression is Altered with Metformin.
    Archives of medical research, 2020, Volume: 51, Issue:4

    Topics: Adult; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Foot; Down-Regulation; Female; Humans; M

2020
[Evaluation of primary adherence to medications in patients with chronic conditions: A retrospective cohort study].
    Atencion primaria, 2018, Volume: 50, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chronic Disease; Cohort

2018
Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease.
    Annals of vascular surgery, 2019, Volume: 55

    Topics: Aged; Aged, 80 and over; Amputation, Surgical; Chronic Disease; Comorbidity; Diabetes Mellitus; Endo

2019
Metformin inhibits mTOR-HIF-1α axis and profibrogenic and inflammatory biomarkers in thioacetamide-induced hepatic tissue alterations.
    Journal of cellular physiology, 2019, Volume: 234, Issue:6

    Topics: Animals; Biomarkers; Chronic Disease; Hepatocytes; Hypoxia-Inducible Factor 1, alpha Subunit; Inflam

2019
Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy.
    Clinical toxicology (Philadelphia, Pa.), 2014, Volume: 52, Issue:2

    Topics: Acidosis, Lactic; Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Chronic Disease; Creatinine;

2014
Lactic acidosis induced by metformin in a chronic hemodialysis patient with diabetes mellitus type 2.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2014, Volume: 18, Issue:2

    Topics: Acidosis, Lactic; Aged; Chronic Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inc

2014
A multistate model and an algorithm for measuring long-term adherence to medication: a case of diabetes mellitus type 2.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2014, Volume: 17, Issue:2

    Topics: Age Factors; Algorithms; Chronic Disease; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Humans

2014
Impact of diabetes type II and chronic inflammation on pancreatic cancer.
    BMC cancer, 2015, Feb-13, Volume: 15

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Cell Death; Cell Line, Tumor; Cell

2015
Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes.
    Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:4

    Topics: Aged; Chronic Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-U

2015
Can We Stop Aging?
    Scientific American, 2015, Volume: 313, Issue:1

    Topics: Aged, 80 and over; Aging; Animals; Bone Morphogenetic Proteins; Chronic Disease; Everolimus; Growth

2015
Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension.
    American journal of respiratory cell and molecular biology, 2016, Volume: 55, Issue:3

    Topics: Animals; Cell Proliferation; Cells, Cultured; Chronic Disease; Gene Deletion; Hyperplasia; Hypertens

2016
Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 85

    Topics: Animals; Behavior, Animal; Biomarkers; Chronic Disease; Depression; Diet, High-Fat; Disease Models,

2017
Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis.
    Journal of immunology (Baltimore, Md. : 1950), 2009, Jun-15, Volume: 182, Issue:12

    Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Central Nervous System; Chronic Disease; Cy

2009
Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension.
    British journal of pharmacology, 2009, Volume: 158, Issue:5

    Topics: Animals; Cell Proliferation; Chronic Disease; Endothelium, Vascular; Enzyme Activation; Hemodynamics

2009
Can technology improve adherence to long-term therapies?
    Journal of diabetes science and technology, 2009, May-01, Volume: 3, Issue:3

    Topics: Biotechnology; Chronic Disease; Communication; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypog

2009
Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:5

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Chronic Disease; Diabetes Mellitus, Ty

2010
Metformin prevents the development of chronic heart failure in the SHHF rat model.
    Diabetes, 2012, Volume: 61, Issue:4

    Topics: Animals; Blood Glucose; Blood Pressure; Chronic Disease; Gene Expression Regulation; Heart Failure;

2012
Diabetic ketoacidosis in a patient with chronic calcific pancreatitis after minor papilla stent insertion.
    Gastrointestinal endoscopy, 2004, Volume: 59, Issue:3

    Topics: Alcoholism; Calcinosis; Cholangiopancreatography, Endoscopic Retrograde; Chronic Disease; Diabetic K

2004
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
    Diabetes research and clinical practice, 2004, Volume: 64, Issue:3

    Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Typ

2004
Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?
    Diabetic medicine : a journal of the British Diabetic Association, 2006, Volume: 23, Issue:3

    Topics: Adult; Body Mass Index; Chronic Disease; Delivery, Obstetric; Diabetes Mellitus, Type 2; Female; Fet

2006
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2007, Volume: 58, Issue:2

    Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte

2007
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2007, Volume: 58, Issue:2

    Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte

2007
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2007, Volume: 58, Issue:2

    Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte

2007
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2007, Volume: 58, Issue:2

    Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte

2007
[Treatment of diabetics with metformin].
    Vutreshni bolesti, 1980, Volume: 19, Issue:4

    Topics: Adult; Aged; Chronic Disease; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Retinopathy; Drug

1980
The prevalence of chronic diarrhea among diabetic patients.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Autonomic Nervous System Dis

1999
Metformin as a cause of late-onset chronic diarrhea.
    Pharmacotherapy, 2001, Volume: 21, Issue:11

    Topics: Chronic Disease; Diabetes Mellitus, Type 2; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin

2001